4D Molecular Therapeutics’ (FDMT) “Outperform” Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reiterated their outperform rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. Royal Bank Of Canada currently has a $26.00 price target on the stock.

Several other equities research analysts also recently commented on the stock. Roth Capital lowered their price objective on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Finally, Chardan Capital reiterated a “buy” rating and set a $25.00 price objective on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

4D Molecular Therapeutics Stock Down 4.9%

Shares of FDMT opened at $10.00 on Tuesday. The company has a market cap of $467 million, a price-to-earnings ratio of -2.83 and a beta of 2.93. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $11.65. The company has a 50 day moving average of $7.92 and a two-hundred day moving average of $5.35.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. On average, sell-side analysts expect that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC raised its holdings in shares of 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after purchasing an additional 2,674 shares during the last quarter. Quadrature Capital Ltd purchased a new position in shares of 4D Molecular Therapeutics during the second quarter worth $42,000. Los Angeles Capital Management LLC purchased a new position in shares of 4D Molecular Therapeutics during the second quarter worth $42,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics during the first quarter worth $39,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of 4D Molecular Therapeutics during the first quarter worth $41,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.